Abstract
Targeting tumor-derived angiogenesis has emerged as a promising new treatment strategy in patients with glioblastoma. Cediranib (Recentin™) is a potent oral inhibitor of vascular endothelial growth factor (VEGF) receptors and has demonstrated improved progression-free survival in an uncontrolled phase II study of patients with recurrent glioblastoma. The drug is taken orally, once daily, and has a manageable side effect profile. In addition, it has potent anti-edema and steroid-sparing effects that might improve the quality of life of glioblastoma patients. Several clinical trials are ongoing testing cediranib in patients with gliomas.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Radiopharmaceuticals
Recent Patents on Anti-Cancer Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents
Current Cancer Therapy Reviews
Clinical Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents